Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Communications and UpdatesFull Access

Disclosure of Editors’ Financial Relationships

Published Online:1 Jan 2024https://doi.org/10.1176/appi.ajp.24181001

The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Ned H. Kalin, M.D. (Editor-in-Chief): Dr. Kalin reports serving as a consultant to the Board of Scientific Advisors, Pritzker Neuropsychiatric Disorders Consortium; Skyland Trail National Advisory Board, Corcept Therapeutics Incorporated, Institute for Early Adversity Research External Scientific Advisory Board at the University of Texas-Austin, and Galen Mental Health Advisory Board.

Elisabeth B. Binder, M.D., Ph.D. (Deputy Editor): Dr. Binder reports no financial relationships with commercial interests.

Kathleen T. Brady, M.D., Ph.D. (Deputy Editor): Dr. Brady reports serving as a consultant to Alkermes Pharmaceuticals, Embera Pharma, Genomind, Indivior Pharmaceuticals, Sage Pharmaceuticals, Skyland Trail Treatment Center.

David A. Lewis, M.D. (Deputy Editor): Dr. Lewis reports currently receiving investigator-initiated research support from Merck.

William M. McDonald, M.D. (Deputy Editor): Dr. McDonald reports receiving compensation as the Chair of the Data and Safety Monitoring Board for an NIA-sponsored multicenter study; serving on the Board of Skyland Trail and 3Keys; serving as a consultant for Sage Therapeutics and Signant Health; and receiving past funding from Cervel Neurotherapeutics, NeoSync, Neuronetics, Soterix, and the Stanley Foundation.

Daniel S. Pine, M.D. (Deputy Editor): Dr. Pine reports no financial relationships with commercial interests.

Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor): Dr. Rodriguez reports in the past 3 years having served as a consultant to Biogen, Biohaven Pharmaceuticals, and Osmind; receiving grant support from Biohaven Pharmaceuticals; receiving a stipend for her role as Deputy Editor of Neuropsychopharmacology; and receiving royalties from American Psychiatric Association Publishing. [Updated online on April 2, 2024.]